Phillips-Medisize, a Molex company, today announced that MedTech Breakthrough, an independent organisation that recognizes the top companies and solutions in the global health and medical technology market, has selected its Connected Health Platform (CHP) as the winner of its Best Overall Connected Healthcare Solution award in the 2019 MedTech Breakthrough Awards programme.
Incorporating more than a decade of experience in developing connected health solutions, the Phillips-Medisize CHP encompasses extensive information-sharing, analytics capabilities, robust cybersecurity and streamlined regulatory documentation to support medical device, pharmaceutical and diagnostics companies.
"We extend a hearty congratulations to the Phillips-Medisize team on their success and innovation in the connected health space and are proud to recognise them as a marquee 2019 MedTech Breakthrough Award winner," said James Johnson, managing director, MedTech Breakthrough. "Their cloud-based CHP helps pharmaceutical companies and drug delivery device developers tackle the worldwide challenge of patient medication adherence, while speeding development time to market and keeping healthcare costs down."
The mission of the MedTech Breakthrough Awards is to honour excellence and recognise the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s programme attracted more than 3,500 nominations from over 15 different countries throughout the world.
"We thank the MedTech Breakthrough organisation for taking the time and effort to acknowledge Phillips-Medisize for our CHP solution," said Matt Jennings, CEO and President of Phillips-Medisize. "We’re honoured to receive this award as a testament that our global team of experts continues to deliver innovative ideas to help transform the diagnosis and delivery of healthcare."
The award-winning Connected Health Platform (CHP) is registered with the FDA as a Medical Device Data System (MDDS) and is designed from the ground up to support patients with their medication regimes and related data. The system includes simple, intuitive mobile apps and reminders to support and motivate users.
Phillips-Medisize’s CHP can track medication usage for multiple drug products, on a global basis, in real-time. The CHP comes with a Software Development Toolkit (SDK) and defined, extensible API, allowing any device to be connected to the system. This enables pharmaceutical companies to deploy a single solution across all therapy areas and drug compounds if desired, instead of having to utilise different companies’ platforms for each product and device type.
Pharmaceutical companies and payer/provider organisations also benefit from the platform’s powerful analytics package, which is designed to connect and display information from connected drug delivery devices, biosensors and regulated Mobile Medical Applications (SaMD/MMA). This enables customers to quickly generate views of their data and create data presentation layers for use by the analytics engine, providing deep insight into how medication is taken.
Additionally, with the Phillips-Medisize CHP being built on InterSystem’s HealthShare technology, the solution benefits from the interoperability ingrained within this technology. This allows the CHP to integrate healthcare data from multiple sources via its enterprise master patient index. The data can be made actionable for payers and providers, allowing connection, via integration, to various EMR and EHR systems.
MD&M East attendees have the opportunity to see the CHP and other Phillips-Medisize medical device solutions at Booth 1615 at the Jacob K. Javits Convention Center in New York, New York – 11-13 June, 2019.